Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19
Matthew G. Johnson, Amy Puenpatom, Pablo Andrés Moncada, et al.
Annals of Internal Medicine (2022) Vol. 175, Iss. 8, pp. 1126-1134
Open Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study
Carlos King Ho Wong, Ivan Chi Ho Au, Kristy T. K. Lau, et al.
The Lancet (2022) Vol. 400, Iss. 10359, pp. 1213-1222
Open Access | Times Cited: 243
Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study
Carlos King Ho Wong, Ivan Chi Ho Au, Kristy T. K. Lau, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 12, pp. 1681-1693
Open Access | Times Cited: 218
Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study
Carlos King Ho Wong, Kristy T. K. Lau, Ivan Chi Ho Au, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 6, pp. 683-695
Open Access | Times Cited: 45
Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients
Joseph F. Standing, Laura Buggiotti, José Afonso Guerra‐Assunção, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 18
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
Kara W. Chew, Carlee Moser, Eric S. Daar, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 43
Drug treatment of COVID-19 infection
Grace Lui, Giovanni Guaraldi
Current Opinion in Pulmonary Medicine (2023) Vol. 29, Iss. 3, pp. 174-183
Open Access | Times Cited: 30
COVID-19 annual update: a narrative review
Michela Biancolella, Vito Luigi Colona, Lucio Luzzatto, et al.
Human Genomics (2023) Vol. 17, Iss. 1
Open Access | Times Cited: 28
Differences between the course of SARS-CoV-2 infections in the periods of the Delta and Omicron variants dominance in Poland
Krystyna Dobrowolska, Michał Brzdęk, Dorota Zarębska‐Michaluk, et al.
Polskie Archiwum Medycyny Wewnętrznej (2023)
Open Access | Times Cited: 22
Efficacy and Safety of Molnupiravir Treatment for COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Fangyuan Tian, Qiyi Feng, Zhaoyan Chen
International Journal of Antimicrobial Agents (2023) Vol. 62, Iss. 2, pp. 106870-106870
Open Access | Times Cited: 22
Molnupiravir: Mechanism of action, clinical, and translational science
Brian M. Maas, Julie Strizki, Randy R. Miller, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 2
Open Access | Times Cited: 8
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Sho Iketani, David D. Ho
Cell chemical biology (2024) Vol. 31, Iss. 4, pp. 632-657
Open Access | Times Cited: 7
Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
Hardik Goswami, Adnan Alsumali, Yiling Jiang, et al.
PharmacoEconomics (2022) Vol. 40, Iss. 7, pp. 699-714
Open Access | Times Cited: 27
Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives
Qiugang Zhu, Yan Xu, Ting Wang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 27
Molnupiravir: From Hope to Epic Fail?
Daniele Focosi
Viruses (2022) Vol. 14, Iss. 11, pp. 2560-2560
Open Access | Times Cited: 26
Real-world effectiveness of early molnupiravir and nirmatrelvir/ritonavir among hospitalized, non-oxygen-dependent COVID-19 patients on admission during Hong Kong’s Omicron BA.2 wave: an observational study
Carlos King Ho Wong, Ivan Chi Ho Au, Kristy T. K. Lau, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 22
Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID‐19: A systematic review and meta‐analysis of randomized control trials
Po‐Yu Huang, Tinghui Liu, Jheng‐Yan Wu, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 3
Closed Access | Times Cited: 12
Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients
Mingyao Sun, Honghao Lai, Jiajie Huang, et al.
Journal of Antimicrobial Chemotherapy (2023) Vol. 78, Iss. 9, pp. 2131-2139
Closed Access | Times Cited: 10
Real-world effectiveness of molnupiravir, azvudine and paxlovid against mortality and viral clearance among hospitalized patients with COVID-19 infection during the omicron wave in China: a retrospective cohort study
Yingsha Chen, Yushi Lin, Huidan Lu, et al.
Diagnostic Microbiology and Infectious Disease (2024) Vol. 109, Iss. 4, pp. 116353-116353
Open Access | Times Cited: 3
Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters
Rana Abdelnabi, Piet Maes, Steven De Jonghe, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 17
Clinical effectiveness of molnupiravir in patients with COVID-19 undergoing haemodialysis
Yi‐Chin Chang, Yi‐Chun Chen, Chiang-Chi Huang, et al.
International Journal of Antimicrobial Agents (2023) Vol. 62, Iss. 1, pp. 106834-106834
Open Access | Times Cited: 9
Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial
Yanfen Guan, Amy Puenpatom, Matthew G. Johnson, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 11, pp. 1521-1530
Open Access | Times Cited: 9
Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial
Sady Alpizar, José Accini, Duane C. Anderson, et al.
Journal of Infection (2023) Vol. 87, Iss. 5, pp. 392-402
Open Access | Times Cited: 9
The effect of molnupiravir on post-acute outcome of COVID-19 survivors
Wan‐Hsuan Hsu, Bo-Wen Shiau, Ya‐Wen Tsai, et al.
Journal of Infection (2023) Vol. 87, Iss. 4, pp. 339-343
Open Access | Times Cited: 8
An Update on SARS-CoV-2 Clinical Trial Results—What We Can Learn for the Next Pandemic
Edi Dharmana, Juliane Brun, Michelle L. Hill, et al.
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 354-354
Open Access | Times Cited: 8
Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19
Young Rock Jang, Yoonju Oh, Jin Yong Kim
Journal of Korean Medical Science (2024) Vol. 39, Iss. 6
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top